(103 days)
Yes
The device description explicitly states "Strain Al is a software as a medical device (SaMD)" and the intended use is for "Strain AI". The name itself strongly suggests the use of AI.
No
The text states that the device is intended as an aid in diagnostic analysis and provides measurements, but it does not directly treat or cure a disease or condition.
No
The device is described as an "aid in diagnostic analysis" and provides quantitative measurements, but it explicitly states that "patient management decisions should not be made solely on the results of the Strain AI analysis." This indicates it is not intended to make a definitive diagnosis itself.
Yes
The device description explicitly states it is "software as a medical device (SaMD)" and is intended to be integrated into a third-party ultrasound imaging device, functioning as a post-processing tool. It does not include any hardware components.
Based on the provided information, it is unlikely that this device is an IVD (In Vitro Diagnostic). Here's why:
- IVD Definition: In Vitro Diagnostics are medical devices used to perform tests on samples taken from the human body (like blood, urine, tissue) to provide information about a person's health. The tests are performed outside the body.
- Strain AI's Function: Strain AI processes images of the heart acquired through ultrasound. It does not analyze biological samples taken from the patient. It's a software tool that analyzes existing medical images.
- Intended Use: The intended use clearly states "noninvasive processing of cardiac ultrasound images." This is an in vivo (within the living body) imaging technique, not an in vitro diagnostic test.
- Device Description: The description reinforces that it's a "software as a medical device (SaMD)" that analyzes "echocardiography data" and "cardiac ultrasound images."
While Strain AI provides information that aids in diagnosis, the method by which it obtains this information (processing images from an in vivo procedure) does not align with the definition of an In Vitro Diagnostic. It falls under the category of medical imaging software.
No
The letter does not state that the FDA has reviewed and approved or cleared a PCCP for this specific device. The section for "Control Plan Authorized (PCCP) and relevant text" explicitly states "Not Found."
Intended Use / Indications for Use
Strain AI is intended for noninvasive processing of cardiac ultrasound images to provide measurements of global longitudinal strain of adult patients with suspected disease.
Product codes
QIH
Device Description
Exo's Strain Al is a software as a medical device (SaMD), intended as an aid in diagnostic analysis of echocardiography data. It specifically measures the global longitudinal strain (GLS) from apical 4-chamber (A4C) cardiac ultrasound images.
This software is developed as a module to be integrated by another computer programmer into their legally marketed ultrasound imaging device.
The software does not have a built-in viewer; instead, it integrates into a third-party ultrasound imaging device. The software functions as a post-processing tool, analyzing images after they are acquired. End-users have the option to accept or reject the provided measurements.
Strain Al takes as input image data and provides as an output a quantitative measurement of the global longitudinal strain (GLS) from apical 4-chamber (A4C) cardiac ultrasound images. It is important to note that patient management decisions should not be made solely on the results of the Strain AI analysis.
Mentions image processing
Yes
Mentions AI, DNN, or ML
Yes
Input Imaging Modality
cardiac ultrasound images
Anatomical Site
Heart
Indicated Patient Age Range
adult patients
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
The test data was entirely separated from the training/validation datasets acquired from independent clinical sites and was not used for any part of the training.
Description of the test set, sample size, data source, and annotation protocol
The clinical performance of the Strain Al was successfully evaluated on test data encompassing diverse demographic variables, including gender, age (ranging from 21 to 96), and ethnicity from multiple clinical sites in metropolitan cities with diverse racial patient populations. The Strain function was evaluated with subjects, on images acquired during a routine clinical practice from cart-based and portable ultrasound devices (with frequency ranging from 1.2 to 4 MHz).
The test data was entirely separated from the training/validation datasets acquired from independent clinical sites and was not used for any part of the training. We established auditability measures, by assigning a unique identification number to each study and its corresponding images.
The ground truth (reference data) was obtained using the reference device.
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
Validation Performance Testing
The clinical performance of the Strain Al was successfully evaluated on test data encompassing diverse demographic variables, including gender, age (ranging from 21 to 96), and ethnicity from multiple clinical sites in metropolitan cities with diverse racial patient populations. The Strain function was evaluated with subjects, on images acquired during a routine clinical practice from cart-based and portable ultrasound devices (with frequency ranging from 1.2 to 4 MHz).
The test data was entirely separated from the training/validation datasets acquired from independent clinical sites and was not used for any part of the training. We established auditability measures, by assigning a unique identification number to each study and its corresponding images.
The ground truth (reference data) was obtained using the reference device. Performance was assessed by calculating the intraclass correlation coefficient (ICC) and root mean square difference (RMSD).
The device performance was also assessed across a wide range of Ultrasound manufacturers and demographic subgroups (Gender, Image source, Age and BMI). The evaluation concluded that the device performance was consistent among clinically meaningful subgroups.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
ICC (95% CI): 0.95 (0.91 - 0.97)
RMSD (95% CI): 2.76 (2.44 - 3.17)
Predicate Device(s)
Reference Device(s)
Predetermined Change Control Plan (PCCP) - All Relevant Information
Not Found
§ 892.2050 Medical image management and processing system.
(a)
Identification. A medical image management and processing system is a device that provides one or more capabilities relating to the review and digital processing of medical images for the purposes of interpretation by a trained practitioner of disease detection, diagnosis, or patient management. The software components may provide advanced or complex image processing functions for image manipulation, enhancement, or quantification that are intended for use in the interpretation and analysis of medical images. Advanced image manipulation functions may include image segmentation, multimodality image registration, or 3D visualization. Complex quantitative functions may include semi-automated measurements or time-series measurements.(b)
Classification. Class II (special controls; voluntary standards—Digital Imaging and Communications in Medicine (DICOM) Std., Joint Photographic Experts Group (JPEG) Std., Society of Motion Picture and Television Engineers (SMPTE) Test Pattern).
0
November 20, 2024
Image /page/0/Picture/1 description: The image shows the logo for the U.S. Food and Drug Administration (FDA). The logo consists of two parts: the Department of Health & Human Services logo on the left and the FDA logo on the right. The FDA logo includes the letters "FDA" in a blue square, followed by the words "U.S. FOOD & DRUG ADMINISTRATION" in blue text.
Exo Inc % Jacqueline Murray Senior Regulatory Affairs Specialist 4201 Burton Drive Santa Clara, California 95054
Re: K242359
Trade/Device Name: Strain AI (SAI001) Regulation Number: 21 CFR 892.2050 Regulation Name: Medical image management and processing system Regulatory Class: Class II Product Code: QIH Dated: October 22, 2024 Received: October 22, 2024
Dear Jacqueline Murray:
We have reviewed your section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (the Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database available at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Additional information about changes that may require a new premarket notification are provided in the FDA guidance documents entitled "Deciding When to Submit a 510(k) for a Change to an Existing Device"
1
(https://www.fda.gov/media/99812/download) and "Deciding When to Submit a 510(k) for a Software Change to an Existing Device" (https://www.fda.gov/media/99785/download).
Your device is also subject to, among other requirements, the Quality System (QS) regulation (21 CFR Part 820), which includes, but is not limited to, 21 CFR 820.30, Design controls; 21 CFR 820.90, Nonconforming product; and 21 CFR 820.100, Corrective and preventive action. Please note that regardless of whether a change requires premarket review, the QS regulation requires device manufacturers to review and approve changes to device design and production (21 CFR 820.30 and 21 CFR 820.70) and document changes and approvals in the device master record (21 CFR 820.181).
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting of medical device-related adverse events) (21 CFR Part 803) for devices or postmarketing safety reporting (21 CFR Part 4, Subpart B) for combination products (see https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reportingcombination-products); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR Part 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR Parts 1000-1050.
All medical devices, including Class I and unclassified devices and combination product device constituent parts are required to be in compliance with the final Unique Device Identification System rule ("UDI Rule"). The UDI Rule requires, among other things, that a device bear a unique device identifier (UDI) on its label and package (21 CFR 801.20(a)) unless an exception or alternative applies (21 CFR 801.20(b)) and that the dates on the device label be formatted in accordance with 21 CFR 801.18. The UDI Rule (21 CFR 830.300(a) and 830.320(b)) also requires that certain information be submitted to the Global Unique Device Identification Database (GUDID) (21 CFR Part 830 Subpart E). For additional information on these requirements, please see the UDI System webpage at https://www.fda.gov/medical-device-advicecomprehensive-regulatory-assistance/unique-device-identification-system-udi-system.
Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to https://www.fda.gov/medical-device-safety/medical-device-reportingmdr-how-report-medical-device-problems.
For comprehensive regulatory information about mediation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/medicaldevices/device-advice-comprehensive-regulatory-assistance) and CDRH Learn
2
(https://www.fda.gov/training-and-continuing-education/cdrh-learn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (https://www.fda.gov/medical-device-advice-comprehensive-regulatoryassistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).
Sincerely,
Samul Risk for
Jessica Lamb, Ph.D. Assistant Director Imaging Software Team DHT8B: Division of Radiological Imaging Devices and Electronic Products OHT8: Office of Radiological Health Office of Product Evaluation and Quality Center for Devices and Radiological Health
Enclosure
3
Indications for Use
510(k) Number (if known) K242359
Device Name Strain AI (SAI001)
Indications for Use (Describe)
Strain AI is intended for noninvasive processing of cardiac ultrasound images to provide measurements of global longitudinal strain of adult patients with suspected disease.
Type of Use (Select one or both, as applicable) |
---|
------------------------------------------------- |
X Prescription Use (Part 21 CFR 801 Subpart D)
| Over-The-Counter Use (21 CFR 801 Subpart C)
CONTINUE ON A SEPARATE PAGE IF NEEDED.
This section applies only to requirements of the Paperwork Reduction Act of 1995.
DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.
The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:
Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff(@fda.hhs.gov
"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."
4
Image /page/4/Picture/0 description: The image shows the logo for EXO. On the left side of the logo, there is a cluster of blue circles that are arranged in a triangular shape. To the right of the circles, the word "EXO" is written in a dark gray sans-serif font. The letters are bold and spaced closely together.
K242359
510(k) Summary
General Information
510(k) Sponsor | Exo Inc. |
---|---|
Address | 4201 Burton Drive |
Santa Clara, CA 95054 | |
Correspondence Person | Jacqueline Murray |
Contact Information | jmurray@exo.inc |
Cell: +1 236-838-5056 | |
Date Prepared | August 8, 2024 |
Proposed Device
Proprietary Name | Strain AI (SAI001) |
---|---|
Common Name | Strain AI |
Classification Name | Automated Radiological Image Processing Software |
Regulation Number | 21 CFR 892.2050 |
Product Code | QIH |
Regulatory Class | II |
Predicate Device
Proprietary Name | LVivo Software Application |
---|---|
Premarket Notification | K210053 |
Classification Name | Automated Radiological Image Processing Software |
Regulation Number | 21 CFR 892.2050 |
Product Code | QIH |
Regulatory Class | II |
Reference Device
Proprietary Name | Us2.v2 |
---|---|
Premarket Notification | K233676 |
Classification Name | Automated Radiological Image Processing Software |
Regulation Number | 21 CFR 892.2050 |
Product Code | QIH |
Regulatory Class | II |
5
Image /page/5/Picture/1 description: The image shows the logo for EXO. The logo consists of two parts: a blue gradient dot pattern on the left and the word "EXO" in dark gray on the right. The dot pattern is made up of 12 dots arranged in a circular shape. The word "EXO" is written in a sans-serif font.
Device Description
Exo's Strain Al is a software as a medical device (SaMD), intended as an aid in diagnostic analysis of echocardiography data. It specifically measures the global longitudinal strain (GLS) from apical 4-chamber (A4C) cardiac ultrasound images.
This software is developed as a module to be integrated by another computer programmer into their legally marketed ultrasound imaging device.
The software does not have a built-in viewer; instead, it integrates into a third-party ultrasound imaging device. The software functions as a post-processing tool, analyzing images after they are acquired. End-users have the option to accept or reject the provided measurements.
Strain Al takes as input image data and provides as an output a quantitative measurement of the global longitudinal strain (GLS) from apical 4-chamber (A4C) cardiac ultrasound images. It is important to note that patient management decisions should not be made solely on the results of the Strain AI analysis.
Indications for Use
Strain Al is intended for noninvasive processing of cardiac ultrasound images to provide measurements of global longitudinal strain of adult patients with suspected disease.
Comparison of Technological Characteristics with the Predicate Device
| Feature/
Function | Subject Device
Strain AI | Predicate Device
LVivo Software Application
(K210053) | Reference Device
Us2.v2 (K233676) |
|---------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------|--------------------------------------|
| Physical
Characteristic | Software package that
operates utilizing
off-the-shelf hardware | Same as subject device | Same as subject device |
| Scan type | Multi-frame ultrasound
images | Same as subject device | Same as subject device |
| Principle of
Operation and
Technology | Ultrasound image
processing software
implementing artificial
intelligence including
non-adaptive machine
learning algorithms trained
with clinical data intended
for non-invasive analysis of
ultrasound data | Same as subject device | Same as subject device |
6
Image /page/6/Picture/1 description: The image shows the logo for EXO. On the left side of the logo is a collection of blue and light blue dots arranged in a circular pattern. To the right of the dots is the word "EXO" in a dark gray sans-serif font. The letters are spaced closely together.
| Feature/
Function | Subject Device
Strain AI | Predicate Device
LVivo Software Application
(K210053) | Reference Device
Us2.v2 (K233676) |
|----------------------|------------------------------------------------------------------------------------|-------------------------------------------------------------|--------------------------------------|
| AI Algorithm | Deep Convolutional Neural
Networks for
Segmentation or
Landmark Detection | Same as Subject
Device | Same as subject device |
| Anatomical Sites | Heart | Heart, Bladder | Same as subject device |
| GLS calculation | Yes | Same as Subject
Device | Same as Subject Device |
Performance Data
Safety and performance of the Strain Al has been evaluated and verified in accordance with software specifications and applicable performance standards through software verification and validation testing. Additionally, the software validation activities were performed in accordance with /EC 62304:2006/AC:2015 - Medical device software - Software life cycle processes, FDA's 'Content of Premarket Submissions for Device Software Functions'' Guidance for Industry and Food and Drug Administration Staff Document issued on June 14, 2023 and FDA Guidance (June 2022) "Technical performance assessment of quantitative imaging in radiological device premarket submissions".
Validation Performance Testing
The clinical performance of the Strain Al was successfully evaluated on test data encompassing diverse demographic variables, including gender, age (ranging from 21 to 96), and ethnicity from multiple clinical sites in metropolitan cities with diverse racial patient populations. The Strain function was evaluated with subjects, on images acquired during a routine clinical practice from cart-based and portable ultrasound devices (with frequency ranging from 1.2 to 4 MHz).
The test data was entirely separated from the training/validation datasets acquired from independent clinical sites and was not used for any part of the training. We established auditability measures, by assigning a unique identification number to each study and its corresponding images.
The ground truth (reference data) was obtained using the reference device. Performance was assessed by calculating the intraclass correlation coefficient (ICC) and root mean square difference (RMSD).
7
Image /page/7/Picture/0 description: The image shows the logo for EXO. The logo consists of two parts: a cluster of blue circles on the left and the word "EXO" in a dark gray sans-serif font on the right. The blue circles are arranged in a pattern that resembles a network or constellation. The word "EXO" is written in all capital letters and has a modern, clean appearance.
The measurement accuracy of Strain Al for cardiac ultrasound images compared with reference data is summarized in Table 1 below:
Table 1: Summary of Strain AI accuracy and reliability for cardiac ultrasound images | ||
---|---|---|
-------------------------------------------------------------------------------------- | -- | -- |
Measurement | ICC (95% CI) | RMSD (95% CI) |
---|---|---|
Global Longitudinal Strain (GLS) | 0.95 (0.91 - 0.97) | 2.76 (2.44 - 3.17) |
The device performance was also assessed across a wide range of Ultrasound manufacturers and demographic subgroups (Gender, Image source, Age and BMI). The evaluation concluded that the device performance was consistent among clinically meaningful subgroups.
Conclusions
Exo's Strain Al is substantially equivalent in intended use, design, principles of operation, technological characteristics, and safety features to the predicate device. There are no different questions of safety and/or effectiveness introduced by the Strain Al when used as intended.